Steven Seedhouse
Stock Analyst at Raymond James
(3.54)
# 825
Out of 5,182 analysts
170
Total ratings
48.81%
Success rate
4.89%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRRO Korro Bio | Upgrades: Outperform | $23 | $13.68 | +68.13% | 4 | Mar 13, 2026 | |
| DNTH Dianthus Therapeutics | Upgrades: Strong Buy | $63 → $123 | $95.76 | +28.45% | 5 | Mar 10, 2026 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $24 → $26 | $9.44 | +175.42% | 2 | Oct 15, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $96.40 | -14.94% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $7.59 | +31.75% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $29.11 | -3.81% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $1.21 | +726.45% | 14 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $35.45 | +193.37% | 20 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $6.09 | +261.25% | 2 | Dec 11, 2024 | |
| PRQR ProQR Therapeutics | Upgrades: Strong Buy | $6 → $14 | $1.99 | +603.52% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $139.77 | -33.46% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $43.45 | +56.50% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $40.85 | +159.52% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $6.30 | +138.10% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $19.98 | +180.28% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $14.94 | +281.53% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $5.69 | +286.64% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $3.37 | +404.45% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $3.88 | +802.06% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $89.00 | -57.30% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $0.45 | +1,008.89% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $67.89 | -44.03% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $8.62 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.19 | - | 14 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.70 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $19.95 | +1,253.38% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $180.54 | - | 2 | Apr 23, 2020 |
Korro Bio
Mar 13, 2026
Upgrades: Outperform
Price Target: $23
Current: $13.68
Upside: +68.13%
Dianthus Therapeutics
Mar 10, 2026
Upgrades: Strong Buy
Price Target: $63 → $123
Current: $95.76
Upside: +28.45%
BioCryst Pharmaceuticals
Oct 15, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $9.44
Upside: +175.42%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $96.40
Upside: -14.94%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $7.59
Upside: +31.75%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $29.11
Upside: -3.81%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $1.21
Upside: +726.45%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $35.45
Upside: +193.37%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $6.09
Upside: +261.25%
ProQR Therapeutics
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $1.99
Upside: +603.52%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $139.77
Upside: -33.46%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $43.45
Upside: +56.50%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $40.85
Upside: +159.52%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $6.30
Upside: +138.10%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $19.98
Upside: +180.28%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $14.94
Upside: +281.53%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $5.69
Upside: +286.64%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $3.37
Upside: +404.45%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $3.88
Upside: +802.06%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $89.00
Upside: -57.30%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $0.45
Upside: +1,008.89%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $67.89
Upside: -44.03%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $8.62
Upside: -
Aug 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $10.19
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.70
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $19.95
Upside: +1,253.38%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $180.54
Upside: -